Campus Alert: Find the latest UMMS campus news and resources at

Page Menu

Hira Lal Goel

UMassMed Faculty Page


Title: Improving Efficacy of VEGF-Targeted Therapy in Prostate Cancer. UMMS16-02; Patent Pending. 

  • This invention discloses methods to improve the response to VEGF/VEGFR-targeted therapy in patients resistant to bevacizumab and sunitinib. Our critical finding is that inhibition of Rac1 activity using a commercially available compound renders resistant cells sensitive to bevacizumab and sunitinib and can therefore be used as an adjuvant to treat aggressive forms of prostate cancer.


Innovation TopicsSmall MoleculesCancerProstate cancerCombination therapySunitinibBevacizuman